Enfortumab vedotin-ejfv (Padcev) receives US Breakthrough Therapy designation for treatment of patients with unresectable locally advanced or metastatic urothelial cancer unable to receive first-line cisplatin-based chemotherapy

This nectin-4-directed antibody and microtubule inhibitor conjugate is already approved in the US for use in adults who have previously received a PD-1 or PD-L1 inhibitor and platinum based chemotherapy. It has not yet been filed for approval in the EU.


Biospace Inc.